Gut Bacterium Reduces Cholesterol Plaque in Mice
The bacterium Bacteroides uniformis produces an acid that lowers plaque by half in initial laboratory studies.
Updated on Oct. 24, 2026 in Life Sciences
Live Poll
Do you believe treatments derived from gut bacteria will be safer or more effective than traditional drugs?
A research study published on October 7, 2026, identifies the gut bacterium Bacteroides uniformis as a regulator of blood cholesterol in mice. The bacterium produces pentadecanoic acid, which inhibits liver enzymes to promote cholesterol clearance.
Why it matters
Current cholesterol treatments like statins often face low long-term patient adherence rates, highlighting the need for alternative biological regulators. Researchers are now exploring how targeting gut microbiota could manage cardiovascular health.
Bacteroides uniformis produces pentadecanoic acid, which blocks the liver enzyme HMG-CoA reductase. This action forces liver cells to increase the expression of LDL receptors, which extract more LDL cholesterol from the blood compared to baseline.
The players
Bacteroides uniformis
A commensal gut bacterium that regulates cholesterol levels by producing pentadecanoic acid.
The details
Bacteroides uniformis acts as a metabolic modulator within the gut. The byproduct it produces, pentadecanoic acid, acts as a natural inhibitor of HMG-CoA reductase—the same enzyme targeted by statins, which are pharmaceutical drugs used to lower blood cholesterol. By inhibiting this enzyme, the liver increases the density of LDL receptors on cell surfaces, accelerating the clearance of low-density lipoprotein (LDL) from the bloodstream. This study represents a preclinical mechanism observed in mice; human-based efficacy remains to be established in future trials.
Timeline
October 7, 2026: Study on Bacteroides uniformis published in Nature.
August 2026: Researchers identified 14 new gut bacterial species.
The Tech Race
This research follows the path established by the 1970s isolation of statins from fungi but shifts the therapeutic target from direct pharmaceutical intervention to microbiome-based regulation. It sits alongside ongoing efforts to leverage gut microbiota to improve outcomes in immunotherapy and metabolic disease.
This research is currently limited to preclinical mouse studies and is not yet available as a therapeutic for humans. Patients seeking cholesterol management should continue to rely on established clinical guidelines while researchers proceed with human-focused study designs.
The takeaway
The study confirms that the gut-liver axis plays a critical role in cholesterol metabolism, marking a departure from traditional drug-only approaches. Watch for future clinical trial results investigating if gut-microbe treatments can improve lipid profiles in humans.
Further reading
Learn more about the latest research in Life Sciences.
Source note: This article includes information reported by Hindustan Times.
Live Poll
Do you believe treatments derived from gut bacteria will be safer or more effective than traditional drugs?
